Olaparib API Market Growth reliant on Capacity Expansion, Regulatory Approvals of Key Drug Candidate pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
New Delhi: "Technology and innovation are the twin engines for growth and IP is the fuel which will transform India into an economic superpower. Make, Design and Protect in India should be the new mantra for IP revolution" says, Shri Piyush Goyal, M
Alembic Pharma share price: Neutral on Alembic Pharma, target price Rs 970: Motilal Oswal indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals Ltd Q1FY22 consolidated PAT slides to Rs. 164.52 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Case filed against AP for taking up projects illegally deccanchronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deccanchronicle.com Daily Mail and Mail on Sunday newspapers.
Global Vaccine Raw Material Demand is Rapidly Growing | Top Companies statistics, Emerging Trends, Supply and Demand, Country wise Opportunity and Research Report to 2021, Says Brandessence Market Research News: Import of COVID Vaccine Raw Material from US: Serum Institute Ask Govt Intervene March 9th, 2021; Serum Institute of India (SII) want the central government involvement in order to unable the firm import important raw materials from the US for nonstop manufacturing and supply of COVID-19 vaccines. Like, Covishield vaccines manufactured by the SII are being extensively used in India and across the worldwide and millions of citizens have been vaccinated by it. Also Serum Institute working on various other COVID-19 vaccines projects in technical collaboration with a variety of institutes such as Novavax, Cadogenix etc. for which it depends on import of many essential products like raw materials, unpreserved and components from different foreign manufacturers, particularly from US.
Healthcare stocks were trading in the negative zone, with the S&P BSE Healthcare index falling 86.07 points or 0.36% at 23952.62 at 13:48 IST. Among the components of the S&P BSE Healthcare index, Morepen Laboratories Ltd (down 5%), Shalby Ltd (down 2.78%),Ipca Laboratories Ltd (down 2.02%),Sun Pharma Advanced Research Company Ltd (down 1.99%),Laurus Labs Ltd (down 1.87%), were the top losers. Among the other losers were Alembic Pharmaceuticals Ltd (down 1.73%), Pfizer Ltd (down 1.72%), Lupin Ltd (down 1.7%), Torrent Pharmaceuticals Ltd (down 1.28%), and Sun Pharmaceuticals Industries Ltd (down 1.27%). On the other hand, Indraprastha Medical Corporation Ltd (up 12.31%), Aarti Drugs Ltd (up 11.31%), and IOL Chemicals & Pharmaceuticals Ltd (up 7.23%) moved up.
Morepen Laboratories Ltd, Future Supply Chain Solutions Ltd, Future Retail Ltd and Alembic Pharmaceuticals Ltd are among the other losers in the BSE s A group today, 05 May 2021. Morepen Laboratories Ltd, Future Supply Chain Solutions Ltd, Future Retail Ltd and Alembic Pharmaceuticals Ltd are among the other losers in the BSE s A group today, 05 May 2021. Future Lifestyle Fashions Ltd lost 5.00% to Rs 55.15 at 14:47 IST.The stock was the biggest loser in the BSE s A group.On the BSE, 60017 shares were traded on the counter so far as against the average daily volumes of 34993 shares in the past one month. Morepen Laboratories Ltd crashed 4.98% to Rs 62. The stock was the second biggest loser in A group.On the BSE, 4.41 lakh shares were traded on the counter so far as against the average daily volumes of 22.98 lakh shares in the past one month.
API supply concerns from China fuel Alembic Pharma’s global prospects May 04, 2021 Company’s segment revenues surge 35% during the year The Covid-led supply disruptions of Active Pharmaceutical Ingredients (API) from China last year has proved to be a blessing in disguise for Alembic Pharma. The API revenues of the Indian drug major during fiscal 2020-21 jumped by 35 per cent following international buyers’ preference for ‘China-plus-one’ strategy to secure key medical inputs. API shortage after Chinese supply disruptions early in 2020 had triggered concerns across the markets for a possible shortage of the raw materials. Speaking to BusinessLine, Pranav Amin, MD, Alembic Pharmaceuticals Ltd, said, “This (API supply disruptions from China) gave an impetus to our API business globally. After second half of the year, Chinese were back in the market and there was competition again. (But) we had secured some markets with existing customers, who adopted a China-plus-one strategy to reduce their dependence on China. They were looking for pharmaceuticals suppliers from India.”
Alembic Pharmaceuticals Ltd Q4FY21 consolidated net profit drops QoQ to Rs. 237.41 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.